Advertisement

Drugs

, Volume 79, Issue 15, pp 1689–1695 | Cite as

Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure

  • Matt ShirleyEmail author
  • Emma H. McCafferty
  • Hannah A. Blair
Adis Drug Evaluation
  • 71 Downloads

Abstract

Lusutrombopag (Mulpleta®), an orally bioavailable, small molecule thrombopoietin receptor agonist, is approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. In placebo-controlled phase 3 clinical trials, lusutrombopag significantly increased the proportion of patients who did not require a platelet transfusion prior to the procedure or rescue therapy for bleeding up to 7 days after the scheduled procedure. Lusutrombopag also significantly increased the proportion of patients who were responders (i.e. had a platelet count ≥ 50 × 109/L and an increase of ≥ 20 × 109/L from baseline) compared with placebo. Lusutrombopag is well tolerated, with headache being the most common adverse reaction in lusutrombopag recipients in clinical trials. Thus, lusutrombopag represents a promising emerging therapeutic option for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Notes

Acknowledgements

During the peer review process, the manufacturer of lusutrombopag was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Matt Shirley, Emma McCafferty and Hannah Blair are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    National Heart Lung and Blood Institute. Thrombocytopenia. 2019. http://www.nhlbi.nih.gov/health-topics/thrombocytopenia. Accessed 22 Aug 2019.
  2. 2.
    Mitchell O, Feldman DM, Diakow M, et al. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39–50.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37(6):778–93.CrossRefGoogle Scholar
  4. 4.
    Maan R, de Knegt RJ, Veldt BJ. Management of thrombocytopenia in chronic liver disease: focus on pharmacotherapeutic strategies. Drugs. 2015;75(17):1981–92.CrossRefGoogle Scholar
  5. 5.
    Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.CrossRefGoogle Scholar
  6. 6.
    Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–7.CrossRefGoogle Scholar
  7. 7.
    Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8(10):899–902.CrossRefGoogle Scholar
  8. 8.
    Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(10):877–83.CrossRefGoogle Scholar
  9. 9.
    Glance LG, Blumberg N, Eaton MP, et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery. Anesthesiology. 2014;120(1):62–75.CrossRefGoogle Scholar
  10. 10.
    Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 1):5–11.CrossRefGoogle Scholar
  11. 11.
    Miller JB, Figueroa EJ, Haug RM, et al. Thrombocytopenia in chronic liver disease and the role of thrombopoietin agonists. Gastroenterol Hepatol (N Y). 2019;15(6):326–32.Google Scholar
  12. 12.
    US FDA. Mulpleta® (lusutrombopag tablets) for oral use: US prescribing information. 2018. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 22 Aug 2019.
  13. 13.
    European Medicines Agency. Lusutrombopag Shionogi: summary of product characteristics. 2019. http://www.ema.europa.eu. Accessed 22 Aug 2019.
  14. 14.
    Japanese Pharmaceuticals and Medical Devices Agency. Lusutrombopag tablets 3 mg: Japanese prescribing information. 2015. http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340018_3399010F1022_1_02. Accessed 7 Jan 2019.
  15. 15.
    Katsube T, Ishibashi T, Kano T, et al. Population pharmacokinetic and pharmacodynamic modeling of lusutrombopag, a newly developed oral thrombopoietin receptor agonist, in healthy subjects. Clin Pharmacokinet. 2016;55(11):1423–33.CrossRefGoogle Scholar
  16. 16.
    Yoshida H, Yamada H, Nogami W, et al. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl. Exp Hematol. 2018;59(30–9):e2.Google Scholar
  17. 17.
    Katsube T, Wajima T, Fukuhara T, et al. Effects of food and calcium carbonate on the pharmacokinetics of lusutrombopag, a novel thrombopoietin receptor agonist. Clin Ther. 2019.  https://doi.org/10.1016/j.clinthera.2019.06.004.CrossRefPubMedGoogle Scholar
  18. 18.
    Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol. 2019;17(6):1192–200.CrossRefGoogle Scholar
  19. 19.
    Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019.  https://doi.org/10.1002/hep.30561.CrossRefPubMedGoogle Scholar
  20. 20.
    Tateishi R, Seike M, Kudo M, et al. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2019;54(2):171–81.CrossRefGoogle Scholar
  21. 21.
    Alkhouri N, Imawari M, Izumi N, et al. Safety and efficacy of lusutrombopag for treatment of thrombocytopenia in subjects with HCC undergoing planned invasive procedures: combined analysis of L-PLUS 1 and L-PLUS 2 trials [abstract no. 0949 plus poster]. In: AASLD—The Liver Meeting®. 2018.Google Scholar
  22. 22.
    Alkhouri N, Imawari M, Izumi N, et al. Efficacy of oral thrombopoietin receptor agonist lusutrombopag in chronic liver disease by underlying disease aetiology [abstract no. SAT-006]. J Hepatol. 2019;70(Suppl 1):e627.CrossRefGoogle Scholar
  23. 23.
    Sasaki R, Shiino C, Imawari M, et al. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: interim results of a postmarketing surveillance. Hepatol Res. 2019.  https://doi.org/10.1111/hepr.13392.CrossRefPubMedGoogle Scholar
  24. 24.
    Afdhal N, Brown R, Izumi N, et al. Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure: pooled safety analysis from 3 studies [abstract no. SAT-002]. J Hepatol. 2019;70(Suppl 1):e625.CrossRefGoogle Scholar
  25. 25.
    US FDA. Doptelet® (avatrombopag) tablets, for oral use: US prescribing information. 2019. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 22 Aug 2019.
  26. 26.
    European Medicines Agency. Doptelet (avatrombopag): summary of product characteristics. 2019. http://www.ema.europa.eu. Accessed 30 Aug 2019.
  27. 27.
    Takada H, Kurosaki M, Nakanishi H, et al. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. PLoS One. 2019;14(2):e0211122.CrossRefGoogle Scholar
  28. 28.
    Katsube T, Shimizu R, Fukuhara T, et al. Pharmacokinetic/pharmacodynamic modelling and simulation of lusutrombopag, a novel thrombopoietin receptor agonist, for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures. Clin Pharmacokinet. 2019.  https://doi.org/10.1007/s40262-019-00770-4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Matt Shirley
    • 1
    Email author
  • Emma H. McCafferty
    • 1
  • Hannah A. Blair
    • 1
  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations